Actively Recruiting

Phase 1
Phase 2
Age: 12Years +
All Genders
NCT03093116

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Led by Turning Point Therapeutics, Inc. · Updated on 2026-04-03

500

Participants Needed

165

Research Sites

573 weeks

Total Duration

On this page

Sponsors

T

Turning Point Therapeutics, Inc.

Lead Sponsor

Z

Zai Lab (Shanghai) Co., Ltd.

Collaborating Sponsor

AI-Summary

What this Trial Is About

Phase 1 dose escalation will determine the first cycle dose-limiting toxicities (DLTs), the maximum tolerated dose (MTD), the biologically effective dose and recommended Phase 2 dose (RP2D) of repotrectinib given to adult subjects with advanced solid malignancies harboring an ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. Midazolam DDI substudy will examine effect of of repotrectinib on CYP3A induction. Phase 2 will determine the confirmed Overall Response Rate (ORR) as assessed by Blinded Independent Central Review (BICR) of repotrectinib in each subject population expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement. The secondary objective will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS) and clinical benefit rate (CBR) of repotrectinib in each expansion cohort of advanced solid tumors that harbor a ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement.

CONDITIONS

Official Title

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Who Can Participate

Age: 12Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Histologically or cytologically confirmed locally advanced or metastatic solid tumor with ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement (Phase 1) or ROS1 or NTRK1-3 gene fusion (Phase 2).
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.
  • Age 12 years or older (or 20 years as per local regulation).
  • Ability to swallow capsules intact.
  • At least one measurable target lesion per RECIST v1.1 (including CNS-only measurable disease).
  • Prior cytotoxic chemotherapy and immunotherapy allowed (Phase 1).
  • Resolution of acute toxic effects from prior therapies to Grade 1 or less (excluding alopecia).
  • Patients with asymptomatic CNS metastases or leptomeningeal carcinomatosis meeting protocol criteria.
  • Baseline laboratory values within specified limits for blood counts, liver and kidney function, and electrolytes.
  • Life expectancy of at least 3 months.
  • For Phase 2, documented ROS1 or NTRK1-3 gene fusion confirmed by local and central laboratory testing.
  • Willingness and ability to provide informed consent or assent (for ages 12-17).
  • Assignment into one of six expansion cohorts based on prior therapy and tumor gene status (Phase 2).
Not Eligible

You will not qualify if you...

  • Concurrent participation in another therapeutic clinical trial.
  • Symptomatic brain metastases or leptomeningeal involvement.
  • History of previous cancer requiring therapy within past 2 years, except certain skin or in situ carcinomas.
  • Major surgery within 4 weeks or recent radiation therapy within 2 weeks before treatment.
  • Clinically significant cardiovascular disease or ongoing serious heart rhythm problems.
  • Prolonged QTc interval or other ECG abnormalities increasing risk of arrhythmia.
  • Known active infections including HIV.
  • Gastrointestinal diseases affecting drug absorption.
  • Peripheral neuropathy of Grade 2 or higher.
  • History of severe interstitial lung disease or pneumonitis except prior radiation pneumonitis.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 165 locations

1

Local Institution - 2129

Duarte, California, United States, 91010

Completed

2

Local Institution - 2120

Glendale, California, United States, 91206

Completed

3

Local Institution - 2136

La Jolla, California, United States, 92037

Withdrawn

4

Local Institution - 2114

La Jolla, California, United States, 92093

Completed

5

Local Institution - 2121

Long Beach, California, United States, 90813

Completed

6

Local Institution - 1001

Orange, California, United States, 92868

Completed

7

Local Institution - 2101

Orange, California, United States, 92868

Completed

8

St Joseph Heritage Healthcare

Santa Rosa, California, United States, 95403

Actively Recruiting

9

Local Institution - 1003

Aurora, Colorado, United States, 80045

Completed

10

Local Institution - 2103

Aurora, Colorado, United States, 80045

Completed

11

Local Institution - 2106

Washington D.C., District of Columbia, United States, 20007

Completed

12

Local Institution - 2110

Washington D.C., District of Columbia, United States, 20016

Completed

13

Memorial Healthcare System

Hollywood, Florida, United States, 33021

Actively Recruiting

14

Local Institution - 2113

Tampa, Florida, United States, 33612

Completed

15

University Cancer and Blood Center

Athens, Georgia, United States, 30607

Actively Recruiting

16

Local Institution - 2134

Columbus, Georgia, United States, 31904

Completed

17

University of Chicago

Chicago, Illinois, United States, 60637

Actively Recruiting

18

Local Institution - 2142

Peoria, Illinois, United States, 61615

Completed

19

Local Institution - 2116

New Orleans, Louisiana, United States, 70121

Not Yet Recruiting

20

Local Institution - 2133

Baltimore, Maryland, United States, 21210

Completed

21

Massachusetts General Hospital,

Boston, Massachusetts, United States, 02114

Actively Recruiting

22

Local Institution - 1004

Boston, Massachusetts, United States, 02214

Completed

23

Local Institution - 2131

Boston, Massachusetts, United States, 02215

Completed

24

Local Institution - 2105

Ann Arbor, Michigan, United States, 48109

Completed

25

Local Institution - 2111

Detroit, Michigan, United States, 48201

Completed

26

Local Institution - 2140

Detroit, Michigan, United States, 48202-2608

Completed

27

Local Institution - 2132

Saint Paul, Minnesota, United States, 55101

Completed

28

Local Institution - 2147

Bolivar, Missouri, United States, 65613

Completed

29

Washington University Infusion Center Pharmacy

St Louis, Missouri, United States, 63110

Actively Recruiting

30

Local Institution - 2122

New Brunswick, New Jersey, United States, 08901

Completed

31

Local Institution - 2117

New York, New York, United States, 10016

Completed

32

Local Institution - 1002

New York, New York, United States, 10065

Active, Not Recruiting

33

Local Institution - 2102

New York, New York, United States, 10065

Completed

34

Local Institution - 2144

Goldsboro, North Carolina, United States, 27534

Completed

35

Local Institution - 2112

Canton, Ohio, United States, 44718

Completed

36

Local Institution - 2143

Cincinnati, Ohio, United States, 45220

Completed

37

Local Institution - 2109

Cleveland, Ohio, United States, 44195

Completed

38

The Ohio State University Wexner Medical Center

Columbus, Ohio, United States, 43210

Actively Recruiting

39

Local Institution - 2119

Toledo, Ohio, United States, 43614

Completed

40

Local Institution - 2108

Philadelphia, Pennsylvania, United States, 19111-2497

Completed

41

Baptist Memorial Hospital Baptist Cancer Center

Memphis, Tennessee, United States, 38120

Actively Recruiting

42

UT Southwestern Medical Center

Dallas, Texas, United States, 75390

Actively Recruiting

43

Local Institution - 2127

Houston, Texas, United States, 77030

Completed

44

MD Anderson Cancer Center

Houston, Texas, United States, 77030

Actively Recruiting

45

Local Institution - 2146

Kingwood, Texas, United States, 77339

Completed

46

Local Institution - 2137

Fairfax, Virginia, United States, 22031

Completed

47

Local Institution - 2107

Seattle, Washington, United States, 98109

Completed

48

Local Institution - 2141

Tacoma, Washington, United States, 98405

Withdrawn

49

Local Institution - 2145

Appleton, Wisconsin, United States, 54911

Completed

50

Chris O'Brien LifeHouse

Camperdown, New South Wales, Australia, 2050

Actively Recruiting

51

Local Institution - 6103

Adelaide, South Australia, Australia, 5042

Completed

52

Peter MacCallum Cancer Centre

Melbourne, Victoria, Australia, 3000

Actively Recruiting

53

Local Institution - 3301

East Melbourne, Australia, 3002

Completed

54

Local Institution - 4802

Antwerp, Belgium, 2650

Completed

55

Local Institution - 4801

Leuven, Belgium, 3000

Completed

56

Local Institution - 2202

Edmonton, Alberta, Canada, T6G 1Z2

Completed

57

Local Institution - 2205

Vancouver, British Columbia, Canada, V5Z 4E7

Withdrawn

58

Local Institution - 2201

Toronto, Ontario, Canada, M5G 2M9

Completed

59

Local Institution - 6503

Toronto, Ontario, Canada, M5G 2M9

Active, Not Recruiting

60

Local Institution - 2203

Ontario, Canada, L6R 37R

Completed

61

Local Institution - 2204

Ottawa, Canada, K1H 8L6

Completed

62

Local Institution - 6702

Beijing, Beijing Municipality, China, 100021

Completed

63

Beijing Cancer hospital

Beijing, Beijing Municipality, China, 100142

Actively Recruiting

64

Daping Hospital, the Third Affiliated Hospital of Third Military Medical University /Cancer Center

Daping, Chongqing Municipality, China, 00000

Actively Recruiting

65

Local Institution - 6719

Fuzhou, Fujian, China, 000000

Completed

66

The First Affiliated hospital of Xiamen University-oncology

Xiamen, Fujian, China, 361003

Actively Recruiting

67

Guangdong Provincial People'S Hospital

Guangzhou, Guangdong, China, 510120

Actively Recruiting

68

Local Institution - 6733

Guangzhou, Guangdong, China, 510120

Completed

69

Local Institution - 6505

Shenzhen, Guangdong, China, 518053

Active, Not Recruiting

70

The Affiliated Tumor Hospital of Harbin Medical University

Harbin, Heilongjiang, China, 150081

Actively Recruiting

71

Local Institution - 6504

Shatin, HONG KONG, China, 999077

Active, Not Recruiting

72

Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology/Cancer Center Department

Wuhan, Hubei, China, 430022

Actively Recruiting

73

Local Institution - 6705

Changsha, Hunan, China, 410011

Completed

74

Hunan Cancer Hospital-thoracic oncology II

Changsha, Hunan, China, 410013

Actively Recruiting

75

Local Institution - 6748

Nanjing, Jiangsu, China, 210008

Completed

76

XuZhou Central Hospital/Oncology Department

Xuzhou, Jiangsu, China, 00000

Actively Recruiting

77

Jilin Cancer Hospital/Medical Oncology Department

Changchun, Jilin, China, 130012

Actively Recruiting

78

Jilin Cancer Hospital/Medical Oncology Department

Changchun, Jilin, China, 130012

Actively Recruiting

79

The first hospital of Jilin university-Oncology Department

Changchun, Jilin, China, 130021

Actively Recruiting

80

Liaoning Cancer Hospital

Shenyang, Liaoning, China, 110801

Actively Recruiting

81

Tangdu Hospital

Xi'an, Shan3xi, China, 710038

Actively Recruiting

82

Shanxi Bethune Hospital

Taiyuan, Shanxi, China, 030032

Actively Recruiting

83

Sichuan Cancer Hospital/Medical Oncology Department

Chengdu, Sichuan, China, 00000

Actively Recruiting

84

The First Hospital Affiliated To AMU - Southwest Hospital

Chongqing, Sichuan, China, 400030

Actively Recruiting

85

Local Institution - 6725

Hangzhou, Zhejiang, China, 310016

Completed

86

Zhejiang Cancer Hospital-Oncology

Hangzhou, Zhejiang, China, 310022

Actively Recruiting

87

The Third Xiangya Hospital of Central South University/Department of Respiratory and Critical Care Medicine

Changsha, China, 00000

Actively Recruiting

88

West China Hospital Sichuan University/Lung cancer center

Chengdu, China, 00000

Actively Recruiting

89

The First Affiliated Hospital - Zhejiang University School of Medicine

Hangzhou, China, 310003

Actively Recruiting

90

Anhui Provincial Hospital

Hefei, China, 230001

Actively Recruiting

91

Shanghai Chest Hospital

Shanghai, China, 200030

Actively Recruiting

92

Shanghai Chest Hospital

Shanghai, China, 200030

Actively Recruiting

93

Weifang People's Hospital/Medical Oncology Department

Weifang, China, 00000

Actively Recruiting

94

Henan Cancer Hospital/The 1st pneumology department

Zhengzhou, China, 00000

Actively Recruiting

95

Local Institution - 4901

Copenhagen, Denmark, 2100

Completed

96

Local Institution - 4201

Marseille, Bouches-du-Rhône, France, 13005

Completed

97

Local Institution - 4207

Brest, France, 29200

Completed

98

Centre Georges-Francois Leclerc

Dijon, France, 21079

Actively Recruiting

99

Centre Hospitalier Universitarie Grenoble Alpes (Chuga)

Grenoble, France, 38043

Actively Recruiting

100

Centre Antoine-Lacassagne

Nice, France, 06189

Actively Recruiting

101

Local Institution - 4208

Poitiers, France, 86000

Completed

102

Local Institution - 4203

Saint-Mandé, France, 94163

Completed

103

Institute Gustave Roussy

Villejuif, France, 98405

Actively Recruiting

104

Local Institution - 4704

Berlin, Germany, 13125

Completed

105

Local Institution - 4701

Cologne, Germany, 50937

Completed

106

Local Institution - 4703

Dresden, Germany, 01307

Completed

107

Local Institution - 4702

Heidelberg, Germany, 69120

Completed

108

Local Institution - 6502

Hong Kong, Hong Kong, 0

Active, Not Recruiting

109

Local Institution - 6501

Hong Kong, Hong Kong

Active, Not Recruiting

110

Local Institution - 5101

Budapest, Hungary, 1083

Completed

111

Local Institution - 5103

Budapest, Hungary, 1121

Completed

112

Fondazione IRCCS Istituto Nazionale dei Tumori

Milan, MI, Italy, 20133

Actively Recruiting

113

Local Institution - 4306

Milan, Italy, 20122

Completed

114

Local Institution - 4307

Palermo, Italy, 90146

Withdrawn

115

Centro di Riferimento Oncologico

Pordenone, Italy, 33081

Actively Recruiting

116

Local Institution - 4304

Ravenna, Italy, 48121

Not Yet Recruiting

117

Local Institution - 4305

Reggio Emilia, Italy, 42123

Completed

118

IRCCS Istituto Regina Elena Oncologia Medica 2

Roma, Italy, 144

Actively Recruiting

119

Local Institution - 4302

Terni, Italy, 05100

Completed

120

Ehime University Hospital

Tōon, Ehime, Japan, 791-0295

Actively Recruiting

121

Hokkaido University Hospital

Sapporo, Hokkaido, Japan, 0608648

Actively Recruiting

122

Kanagawa cancer center

Yokohama, Kanagawa, Japan, 2418515

Actively Recruiting

123

Osaka City General Hospital

Osaka, Osaka, Japan, 5340021

Actively Recruiting

124

National Cancer Center Hospital.

Chuo-ku, Tokyo, Japan, 1040045

Actively Recruiting

125

Tottori University Hospital

Yonago, Tottori, Japan, 683-8504

Actively Recruiting

126

National Cancer Center Hospital East

Kashiwa, Japan, 277-8577

Actively Recruiting

127

Nagoya University Hospital

Nagoya, Japan, 466-8560

Actively Recruiting

128

Osaka International Cancer institute

Osaka, Japan, 5418567

Actively Recruiting

129

Local Institution - 4502

Amsterdam, Netherlands, 1066 CX

Completed

130

Local Institution - 4501

Groningen, Netherlands, 9713 GZ

Completed

131

Ośrodek Badań Klinicznych Wczesnych Faz, Uniwersyteckie Centrum Kliniczne

Gdansk, Poland, 80-214

Actively Recruiting

132

Local Institution - 4604

Lublin, Poland, 20-609

Completed

133

Local Institution - 4605

Poznan, Poland, 60-693

Completed

134

Local Institution - 4603

Szczecin, Poland, 70-784

Completed

135

Local Institution - 4602

Warsaw, Poland, 02-781

Completed

136

National University Hospital

Singapore, Singapore, 119074

Actively Recruiting

137

National Cancer Center Singapore

Singapore, Singapore, 169610

Actively Recruiting

138

Local Institution - 3003

Seoul, Gangnam-gu, South Korea, 06351

Completed

139

Chonnam National University Hwasun Hospital

Hwasun-eup, Hwasun-gun, Jeollanam-do, South Korea, 519-763

Actively Recruiting

140

Local Institution - 3002

Seoul, Seodaemun-gu, South Korea, 03722

Completed

141

Local Institution - 3002

Seoul, Seoul Teugbyeolsi, South Korea, 03080

Withdrawn

142

Seoul National University Hospital

Seoul, Seoul-teukbyeolsi [Seoul], South Korea, 03080

Actively Recruiting

143

Samsung Medical Center

Seoul, Seoul-teukbyeolsi [Seoul], South Korea, 06351

Actively Recruiting

144

Local Institution - 6306

Cheongju-si, South Korea, 28644

Completed

145

Local Institution - 3001

Seoul, South Korea, 03080

Completed

146

Yonsei University Health System, Severance Hospital

Seoul, South Korea, 03722

Actively Recruiting

147

Local Institution - 6307

Seoul, South Korea, 05030

Completed

148

Asan Medical Center

Seoul, South Korea, 05505

Actively Recruiting

149

Local Institution - 6304

Seoul, South Korea, 06591

Completed

150

Local Institution - 4102

Barcelona, Spain, 08028

Completed

151

Hospital Unversitario Val D'Hebrón

Barcelona, Spain, 8035

Actively Recruiting

152

Local Institution - 4106

Madrid, Spain, 28033

Completed

153

START Madrid-FJD

Madrid, Spain, 28040

Actively Recruiting

154

Local Institution - 4103

Madrid, Spain, 28041

Completed

155

Hospital Universitario HM Sanchinarro CIOCC

Madrid, Spain, 28050

Actively Recruiting

156

Local Institution - 4108

Pamplona, Spain, 31008

Completed

157

Local Institution - 4107

Valencia, Spain, 46009

Completed

158

Local Institution - 6201

Taiepi, Taiwan, 100

Active, Not Recruiting

159

Local Institution - 6203

Tainan, Taiwan, 704

Active, Not Recruiting

160

Local Institution - 6202

Taipei, Taiwan, 10449

Completed

161

Local Institution - 4401

London, United Kingdom, SW3 6JJ

Completed

162

Local Institution - 4402

London, United Kingdom, W12 OHS

Completed

163

Local Institution - 4404

London, United Kingdom, W1G 6AD

Completed

164

Local Institution - 4403

Manchester, United Kingdom, M20 4BX

Completed

165

Local Institution - 4405

Sutton, United Kingdom, SM2 5PT

Completed

Loading map...

Research Team

B

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com

CONTACT

F

First line of the email MUST contain NCT # and Site #.

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | DecenTrialz